Dispensary Valuations Shift Beyond EBITDA as Rescheduling Reshapes M&A

Rescheduling Triggers Valuation Framework Overhaul

The DEA's finalization of cannabis rescheduling to Schedule III in April 2026 eliminated the 280E tax burden and triggered a fundamental revaluation of dispensary assets across U.S. markets. Acquirers who previously relied on EBITDA multiples of 4-6x for single-location dispensaries are now conducting deeper operational due diligence, focusing on margin sustainability once the 280E deduction advantage disappears. Cannabis M&A has matured. The land-grab era is over.

Deals closed in May 2026 show acquirers demanding audited financials covering at least 24 months of operations, a departure from the 12-month snapshots common in 2024-2025 transactions. One California-based MSO walked from a $4.2 million dispensary acquisition in Sacramento after forensic accounting revealed the target's gross margin dropped from 52% to 38% when restated without 280E cost-of-goods inflation.

Compliance Infrastructure Now Commands Premium Valuations

Dispensaries with mature seed-to-sale tracking, automated tax remittance systems, and documented SOPs for regulatory audits are receiving valuation premiums of 15-25% over operationally comparable peers without those systems. The premium reflects acquirers' post-close integration costs: retrofitting compliance infrastructure into a legacy dispensary can cost $80,000-$150,000 in consulting fees, software licenses, and staff retraining.

New York's Office of Cannabis Management issued 47 compliance violations to dispensaries in Q1 2026, with 22 of those violations tied to inadequate inventory reconciliation. Acquirers treat state compliance history as a leading indicator of operational discipline. One New Jersey dispensary with zero compliance violations over 36 months commanded a 6.8x EBITDA multiple in a March 2026 sale, compared to the state average of 5.2x.

Margin Sustainability Replaces Revenue Growth as Key Metric

Gross margins above 45% and operating margins above 18% are now baseline thresholds for premium valuations, replacing the revenue-growth benchmarks that dominated 2023-2024 M&A. The recalibration follows the collapse of several high-revenue, low-margin operators who couldn't service acquisition debt once 280E relief exposed their true cost structures.

Illinois dispensaries that maintained operating margins above 20% through the state's 2025 price compression cycle are trading at multiples 1.2-1.5x higher than stores with sub-15% margins, according to deal data from three Chicago-based M&A advisors. The divergence is sharpest in saturated markets where new license issuance has outpaced demand growth.

Scalability Architecture Separates Single Assets from Platform Plays

Acquirers are paying 30-40% premiums for dispensaries with documented playbooks for multi-site replication, including standardized vendor contracts, centralized purchasing systems, and transferable staff training programs. That premium reflects the delta between acquiring a standalone asset and acquiring a template for geographic expansion.

A Pennsylvania dispensary group sold for $18.3 million in April 2026 on the strength of its operations manual—a 340-page document covering everything from opening procedures to crisis-communication protocols. The buyer, a Midwest MSO, deployed the manual across four newly acquired Ohio locations within 60 days of closing. Contrast that with a comparable Pennsylvania sale at $12.7 million where the target had no written SOPs and required nine months of post-close operational stabilization.

Customer Data and Retention Metrics Drive Repeat-Business Valuations

Dispensaries with customer retention rates above 60% and average purchase frequencies exceeding 2.8 visits per month are commanding valuations 20-35% above stores reliant on transient foot traffic. Acquirers model customer lifetime value as a predictor of revenue stability in maturing markets where customer acquisition costs are rising.

Massachusetts dispensaries with loyalty programs that captured at least 70% of transactions in a structured CRM system sold at an average 6.1x EBITDA multiple in Q1 2026, compared to 4.9x for stores with fragmented or paper-based customer data. One Boston-area dispensary's CRM data revealed that its top 18% of customers generated 61% of revenue, a metric the acquirer used to justify a $9.8 million purchase price for a store generating $6.4 million in annual revenue.

Real Estate Control and Lease Terms Reshape Deal Structures

Dispensaries with owned real estate or lease terms longer than 10 years with renewal options are receiving all-cash offers 25-30% above market, while month-to-month or short-term leases are forcing sellers into earn-out structures or discounted multiples. The bifurcation reflects acquirers' need for long-term site control in markets where zoning restrictions limit new dispensary locations.

A Colorado dispensary with a 15-year lease and two five-year options sold for $7.2 million in March 2026, while a comparable store three miles away with a lease expiring in 18 months sold for $4.9 million with 40% of the purchase price tied to a three-year earn-out. Lease terms alone drove the $2.3 million valuation gap, according to the broker who handled both transactions.

Watch for this next: acquirers are beginning to demand environmental audits for dispensaries operating in buildings constructed before 1980, a diligence layer borrowed from commercial real estate M&A and virtually absent from cannabis deals prior to 2026.